We reached out to Fountain’s CEO John Dimos to see what more we can learn about the mysterious San Francisco start-up. When it comes to AI and Longevity drug discovery, there are already several companies out there leveraging the power of machine learning, and we recently covered the $6 million funding injection received by Fountain Therapeutics for …
Fountain’s ‘hypothesis-free’ approach to Longevity AI Read More »
Closing brings total Series A financing sum to $11 million Funds to support expansion of team, technology platform and in vivo preclinical drug testing SAN FRANCISCO, May 19, 2020 (GLOBE NEWSWIRE) — Fountain Therapeutics (“Fountain”), a biopharmaceutical company building a pipeline of therapeutics to treat age-related diseases by reversing cellular age, today announced the closing of a …
Fountain Therapeutics Closes $6 Million Series A-1 Financing Read More »
Fountain Therapeutics Inc., a California company working to create treatments for age-related diseases, said Khosla Ventures has led a $6 million series A-1 financing of the startup, with participation from Nan Fung Life Sciences, which earlier contributed $5 million to the round.
Stanford Medicine professors Michele Barry, Howard Chang, Thomas Clandinin and Thomas Rando were among the 15 Stanford faculty members elected to the American Academy of Arts and Sciences.
